Zomedica Pharmaceuticals Corp (ZOM)
$0.13
0.0001 (0.08%)
ZOM Stock Quote Delayed 30 Minutes
ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023
ZOM stock results show that Zomedica beat on revenue for the fourth quarter of 2023.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
127.49M
PE Ratio
-3.61
EPS
-0.036
Volume (Avg. Vol.)
1.38M
Day's Range
$0.13 - $0.13
52-Week Range
$0.12 - $0.25
Dividend & Yield
N/A (N/A)
ZOM Stock Predictions, Articles, and Zomedica Pharmaceuticals Corp News
Why Is Zomedica (ZOM) Stock Up Today?
Zomedica (ZOM) stock is on the rise Wednesday after the company signed a strategic restructuring agreement with Qorvo Biotechnologies.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time for a breakdown of the biggest pre-market stock movers for Tuesday and the news that has them moving.
ZOM Stock Pops 5% as Zomedica Acquires Revo Squared
ZOM stock is on the rise as Zomedica acquires crucial technology that will provide veterinarians with enhanced diagnostic imaging quality.
Dogs Win, Investors Lose With Zomedica
Zomedica said last year that Truforma would revolutionize veterinary care with radio waves. Now it would rather talk about PulseVet, which it bought in October
It’s Going to Take a Lot to Get Zomedica Stock Out of the Doghouse
ZOM stockholders are likely to grow increasingly frustrated with management's misplaced optimism and the lack of Truforma sales.
Will the PulseVet Acquisition Continue to Deliver Sales for Zomedica?
Zomedica Corp. (NYSEAMERICAN:ZOM) finally has a catalyst that could be a game-changer. It has reported $4.1 million in revenue for full-year 2021. This is big…
Zomedica’s Shareholders Should Be Worried About the Outlook of ZOM Stock
ZOM stock has been a toxic asset for nearly a year, and Zomedica isn't giving investors much to get enthused about.
Zomedica Stock Should Have Popped on This Latest Acquisition, so Beware
Although ZOM stock has some exciting news to undergird its price tag, that hardly anything has changed is worrying.
There’s a Reason to Consider Buying Zomedica, and It’s a Real Shocker
ZOM stock is far from a market darling, but an underreported acquisition could breathe new life into Zomedia's struggling business.
Zomedica Remains a Speculative Play in the Veterinary Field
The dismal run of ZOM Stock likely to continue for the foreseeable future, until it meaningfully improves its top and bottom-line numbers.
